Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
1.800
0.00 (0.00%)
Dec 5, 2025, 4:00 PM EST - Market closed
Palisade Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
268.21M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PALI News
- 4 days ago - Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development - GlobeNewsWire
- 11 days ago - Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations - GlobeNewsWire
- 6 weeks ago - Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) - GlobeNewsWire
- 7 weeks ago - Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewsWire
- 2 months ago - Palisade Bio Announces Cancellation of Special Meeting of Stockholders - GlobeNewsWire
- 2 months ago - Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 2 months ago - Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - GlobeNewsWire